Gag mutations can impact virological response to dual-boosted protease inhibitor combinations in antiretroviral-naïve HIV-infected patients. 2010

Lucile Larrouy, and C Chazallon, and R Landman, and C Capitant, and G Peytavin, and G Collin, and C Charpentier, and A Storto, and G Pialoux, and C Katlama, and P M Girard, and P Yeni, and J P Aboulker, and F Brun-Vezinet, and D Descamps, and
AP-HP, Groupe Hospitalier Bichat-Claude Bernard, Laboratoire de Virologie, Paris F-75018, France.

ANRS 127 was a randomized pilot trial involving naïve patients receiving two dual-boosted protease inhibitor (PI) combinations. Virological response, defined as a plasma HIV RNA level of <50 copies/ml at week 16, occurred in only 41% patients. Low baseline plasma HIV RNA level was the only significant predictor of virological response. The purpose of this study was to investigate the impact on virological response of pretherapy mutations in cleavage sites of gag, gag-pol, and the gag-pol frameshift region. The whole gag gene and protease-coding region were amplified and sequenced at baseline and at week 16 for 48 patients still on the allocated regimen at week 16. No major PI resistance-associated mutations were detected either at baseline or in the 26 patients who did not achieve virological response at week 16. Baseline cleavage site substitutions in the product of the gag open reading frame at positions 128 (p17/p24) (P = 0.04) and 449 (p1/p6(gag)) (P = 0.01) were significantly more frequent in those patients not achieving virological response. Conversely, baseline cleavage site mutation at position 437 (TFP/p6(pol)) was associated with virological response (P = 0.04). In multivariate analysis adjusted for baseline viral load, these 3 substitutions remained independently associated with virological response. We demonstrated here, in vivo, an impact of baseline polymorphic gag mutations on virological response in naïve patients receiving a combination of two protease inhibitors. However, it was not possible to link the substitutions selected under PI selective pressure with virological failure.

UI MeSH Term Description Entries
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D010802 Phylogeny The relationships of groups of organisms as reflected by their genetic makeup. Community Phylogenetics,Molecular Phylogenetics,Phylogenetic Analyses,Phylogenetic Analysis,Phylogenetic Clustering,Phylogenetic Comparative Analysis,Phylogenetic Comparative Methods,Phylogenetic Distance,Phylogenetic Generalized Least Squares,Phylogenetic Groups,Phylogenetic Incongruence,Phylogenetic Inference,Phylogenetic Networks,Phylogenetic Reconstruction,Phylogenetic Relatedness,Phylogenetic Relationships,Phylogenetic Signal,Phylogenetic Structure,Phylogenetic Tree,Phylogenetic Trees,Phylogenomics,Analyse, Phylogenetic,Analysis, Phylogenetic,Analysis, Phylogenetic Comparative,Clustering, Phylogenetic,Community Phylogenetic,Comparative Analysis, Phylogenetic,Comparative Method, Phylogenetic,Distance, Phylogenetic,Group, Phylogenetic,Incongruence, Phylogenetic,Inference, Phylogenetic,Method, Phylogenetic Comparative,Molecular Phylogenetic,Network, Phylogenetic,Phylogenetic Analyse,Phylogenetic Clusterings,Phylogenetic Comparative Analyses,Phylogenetic Comparative Method,Phylogenetic Distances,Phylogenetic Group,Phylogenetic Incongruences,Phylogenetic Inferences,Phylogenetic Network,Phylogenetic Reconstructions,Phylogenetic Relatednesses,Phylogenetic Relationship,Phylogenetic Signals,Phylogenetic Structures,Phylogenetic, Community,Phylogenetic, Molecular,Phylogenies,Phylogenomic,Reconstruction, Phylogenetic,Relatedness, Phylogenetic,Relationship, Phylogenetic,Signal, Phylogenetic,Structure, Phylogenetic,Tree, Phylogenetic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D015999 Multivariate Analysis A set of techniques used when variation in several variables are studied simultaneously. In statistics, multivariate analysis is interpreted as any analytic method that allows simultaneous study of two or more dependent variables. Analysis, Multivariate,Multivariate Analyses
D017320 HIV Protease Inhibitors Inhibitors of HIV PROTEASE, an enzyme required for production of proteins needed for viral assembly. HIV Protease Inhibitor,Inhibitor, HIV Protease,Inhibitors, HIV Protease,Protease Inhibitor, HIV,Protease Inhibitors, HIV
D017386 Sequence Homology, Amino Acid The degree of similarity between sequences of amino acids. This information is useful for the analyzing genetic relatedness of proteins and species. Homologous Sequences, Amino Acid,Amino Acid Sequence Homology,Homologs, Amino Acid Sequence,Homologs, Protein Sequence,Homology, Protein Sequence,Protein Sequence Homologs,Protein Sequence Homology,Sequence Homology, Protein,Homolog, Protein Sequence,Homologies, Protein Sequence,Protein Sequence Homolog,Protein Sequence Homologies,Sequence Homolog, Protein,Sequence Homologies, Protein,Sequence Homologs, Protein

Related Publications

Lucile Larrouy, and C Chazallon, and R Landman, and C Capitant, and G Peytavin, and G Collin, and C Charpentier, and A Storto, and G Pialoux, and C Katlama, and P M Girard, and P Yeni, and J P Aboulker, and F Brun-Vezinet, and D Descamps, and
October 2012, The Journal of antimicrobial chemotherapy,
Lucile Larrouy, and C Chazallon, and R Landman, and C Capitant, and G Peytavin, and G Collin, and C Charpentier, and A Storto, and G Pialoux, and C Katlama, and P M Girard, and P Yeni, and J P Aboulker, and F Brun-Vezinet, and D Descamps, and
July 2019, AIDS (London, England),
Lucile Larrouy, and C Chazallon, and R Landman, and C Capitant, and G Peytavin, and G Collin, and C Charpentier, and A Storto, and G Pialoux, and C Katlama, and P M Girard, and P Yeni, and J P Aboulker, and F Brun-Vezinet, and D Descamps, and
March 2009, The Journal of antimicrobial chemotherapy,
Lucile Larrouy, and C Chazallon, and R Landman, and C Capitant, and G Peytavin, and G Collin, and C Charpentier, and A Storto, and G Pialoux, and C Katlama, and P M Girard, and P Yeni, and J P Aboulker, and F Brun-Vezinet, and D Descamps, and
April 2011, Antimicrobial agents and chemotherapy,
Lucile Larrouy, and C Chazallon, and R Landman, and C Capitant, and G Peytavin, and G Collin, and C Charpentier, and A Storto, and G Pialoux, and C Katlama, and P M Girard, and P Yeni, and J P Aboulker, and F Brun-Vezinet, and D Descamps, and
March 2021, Journal of infection in developing countries,
Lucile Larrouy, and C Chazallon, and R Landman, and C Capitant, and G Peytavin, and G Collin, and C Charpentier, and A Storto, and G Pialoux, and C Katlama, and P M Girard, and P Yeni, and J P Aboulker, and F Brun-Vezinet, and D Descamps, and
January 2013, AIDS (London, England),
Lucile Larrouy, and C Chazallon, and R Landman, and C Capitant, and G Peytavin, and G Collin, and C Charpentier, and A Storto, and G Pialoux, and C Katlama, and P M Girard, and P Yeni, and J P Aboulker, and F Brun-Vezinet, and D Descamps, and
April 2007, The Journal of infection,
Lucile Larrouy, and C Chazallon, and R Landman, and C Capitant, and G Peytavin, and G Collin, and C Charpentier, and A Storto, and G Pialoux, and C Katlama, and P M Girard, and P Yeni, and J P Aboulker, and F Brun-Vezinet, and D Descamps, and
March 2007, HIV medicine,
Lucile Larrouy, and C Chazallon, and R Landman, and C Capitant, and G Peytavin, and G Collin, and C Charpentier, and A Storto, and G Pialoux, and C Katlama, and P M Girard, and P Yeni, and J P Aboulker, and F Brun-Vezinet, and D Descamps, and
January 2019, HIV research & clinical practice,
Lucile Larrouy, and C Chazallon, and R Landman, and C Capitant, and G Peytavin, and G Collin, and C Charpentier, and A Storto, and G Pialoux, and C Katlama, and P M Girard, and P Yeni, and J P Aboulker, and F Brun-Vezinet, and D Descamps, and
January 2002, HIV clinical trials,
Copied contents to your clipboard!